Cargando…
Cannabinoid use and effects in patients with epidermolysis bullosa: an international cross-sectional survey study
BACKGROUND: Epidermolysis bullosa (EB) patient anecdotes and case reports indicate that cannabinoid-based medicines (CBMs) may alleviate pain and pruritus and improve wound healing. CBM use has not been characterized in the EB patient population. OBJECTIVES: To evaluate CBM use among EB patients, in...
Autores principales: | Schräder, Nicholas H. B., Gorell, Emily S., Stewart, Roy E., Duipmans, José C., Harris, Nicole, Perez, Victoria A., Tang, Jean Y., Wolff, André P., Bolling, Marieke C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419930/ https://www.ncbi.nlm.nih.gov/pubmed/34488820 http://dx.doi.org/10.1186/s13023-021-02010-0 |
Ejemplares similares
-
Identifying Epidermolysis Bullosa Patient Needs and Perceived Treatment Benefits: An Explorative Study Using the Patient Benefit Index
por: Schräder, Nicholas H. B., et al.
Publicado: (2021) -
Patients’ and parents’ experiences during wound care of epidermolysis bullosa from a dyadic perspective: a survey study
por: Mauritz, Petra J., et al.
Publicado: (2022) -
Combined tetrahydrocannabinol and cannabidiol to treat pain in epidermolysis bullosa: a report of three cases
por: Schräder, N.H.B., et al.
Publicado: (2018) -
The C4EB study—Transvamix (10% THC / 5% CBD) to treat chronic pain in epidermolysis bullosa: A protocol for an explorative randomized, placebo controlled, and double blind intervention crossover study
por: Schräder, Nicholas H. B., et al.
Publicado: (2022) -
The importance of accurate epidemiological data of epidermolysis bullosa
por: Baardman, Rosalie, et al.
Publicado: (2022)